DrugId:  1
1. Name:  Bacillus calmette-guerin substrain danish 1331 live antigen
2. Groups:  Investigational
3. Description:  BCG SSI has been used in trials studying Tuberculosis.
4. Indication:  Not Available
DrugId:  2
1. Name:  Tuberculin Purified Protein Derivative
2. Groups:  Approved
3. Description:  Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with Mycobacterium tuberculosis through early diagnosis and appropriate therapeutic intervention. The purified protein fraction is isolated from culture media filtrates of a human strain of Mycobacterium tuberculosis. It is included in the World Health Organization's List of Essential Medicines.
4. Indication:  Indicated as a diagnostic agent in Mantoux Test used to detect infection with Mycobacterium tuberculosis. 
DrugId:  3
1. Name:  BCG vaccine
2. Groups:  Investigational
3. Description:  BCG vaccine has been investigated for the treatment of Neoplasms, Bladder Cancer, Neoplasms by Site, Urologic Diseases, and Urologic Neoplasms, among others.
4. Indication:  Not Available
DrugId:  4
1. Name:  Pentavalent Antimony
2. Groups:  Investigational
3. Description:  Pentavalent Antimony has been investigated for the treatment of Cutaneous Leishmaniasis.
4. Indication:  Not Available
DrugId:  5
1. Name:  Antimony
2. Groups:  Investigational
3. Description:  Antimony has been used in trials studying the treatment of Cutaneous Leishmaniasis.
4. Indication:  Not Available
DrugId:  6
1. Name:  Ecromeximab
2. Groups:  Investigational
3. Description:  Ecromeximab has been used in trials studying the treatment of Cutaneous Melanoma and Metastatic Melanoma.
4. Indication:  Not Available
DrugId:  7
1. Name:  Terizidone
2. Groups:  Approved, Investigational
3. Description:  Terizidone has been used in trials studying the treatment of Tuberculosis, HIV Infections, Multidrug Resistant Tuberculosis, and Extensively-drug Resistant Tuberculosis.
4. Indication:  Not Available
DrugId:  8
1. Name:  Ethionamide
2. Groups:  Approved
3. Description:  A second-line antitubercular agent that inhibits mycolic acid synthesis. It also may be used for treatment of leprosy. (From Smith and Reynard, Textbook of Pharmacology, 1992, p868)
4. Indication:  For use in the treatment of pulmonary and extrapulmonary tuberculosis when other antitubercular drugs have failed.
DrugId:  9
1. Name:  Delamanid
2. Groups:  Approved, Investigational
3. Description:  Delamanid is an anti-tuberculosis agent derived from the nitro-dihydro-imidazooxazole class of compounds that inhibits mycolic acid synthesis of bacterial cell wall [1]. It is used in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis (TB) in a combination regimen. Emergence of multidrug-resistant and extensively drug-resistant tuberculosis creates clinical challenges for patients, as the disease is associated with a higher mortality rate and insufficient therapeutic response to standardized antituberculosis treatments as Isoniazid and Rifampicin. Multidrug-resistant tuberculosis may also require more than 2 years of chemotherapy and second-line therapies with narrow therapeutic index [4]. In a clinical study involving patients with pulmonary multidrug-resistant tuberculosis or extensively drug-resistant tuberculosis, treatment of delamanid in combination with WHO-recommended optimised background treatment regimen was associated with improved treatment outcomes and reduced mortality rate [1]. Spontaneous resistance to delamanid was observed during treatment, where mutation in one of the 5 F420 coenzymes responsible for bioactivation of delamanid contributes to this effect [6]. Delamanid is approved by the EMA and is marketed under the trade name Deltyba as oral tablets. It is marketed by Otsuka Pharmaceutical Co., Ltd (Tokyo, Japan).
4. Indication:  Indicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (MDR-TB) in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability [6].
DrugId:  10
1. Name:  Pyrazinamide
2. Groups:  Approved, Investigational
3. Description:  A pyrazine that is used therapeutically as an antitubercular agent.
4. Indication:  For the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents.
DrugId:  11
1. Name:  Talimogene laherparepvec
2. Groups:  Approved, Experimental, Investigational
3. Description:  Talimogene laherparepvec is an oncolytic treatment used in local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with recurrent melanoma. It is a genetically administered herpes simplex virus 1 (HSV-1) that expresses human cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) with antitumor and immune-stimulating activities. It specifically replicates within tumor cells and causes lysis. It was approved by the FDA in 2015 under the market name Imlygic.
4. Indication:  Not Available
DrugId:  12
1. Name:  Ethambutol
2. Groups:  Approved
3. Description:  An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863)
4. Indication:  For use, as an adjunct, in the treatment of pulmonary tuberculosis.
DrugId:  13
1. Name:  Bacillus calmette-guerin substrain tice live antigen
2. Groups:  Approved
3. Description:  Bacillus calmette-guerin substrain tice live antigen is a vaccine containing attenuated live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of Mycobacterium bovis for percutaneous use. It is administered to prevent the development of tuberculosis.
4. Indication:  Not Available
DrugId:  14
1. Name:  Technetium Tc-99m ciprofloxacin
2. Groups:  Investigational
3. Description:  99mTc-Ciprofloxacin is a new formulation of ciprofloxacin (INFECTON), being investigated as a radioimaging agent for the potential diagnosis of infection, including fever of unknown origin, osteomyelitis, wound infection, abdominal abscess, pneumonia, appendicitis and tuberculosis. INFECTON combines the widely used antibiotic, ciprofloxacin, with Technetium ((99m)Tc), the most commonly used radioisotope in nuclear medical imaging There is currently controversy around the drug's ability to discriminate between sterile inflammation and bacterial versus nonbacterial infections.
4. Indication:  Investigated for use/treatment in infectious and parasitic disease (unspecified).
DrugId:  15
1. Name:  Sutezolid
2. Groups:  Investigational
3. Description:  Sutezolid has been used in trials studying the treatment of Tuberculosis.
4. Indication:  Not Available
DrugId:  16
1. Name:  Rifapentine
2. Groups:  Approved, Investigational
3. Description:  Rifapentine is an antibiotic drug used in the treatment of tuberculosis. It inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.
4. Indication:  For the treatment of pulmonary tuberculosis.
DrugId:  17
1. Name:  5-amino-1,3,4-thiadiazole-2-thiol
2. Groups:  Investigational
3. Description:  ATT has been investigated in Pulmonary Tuberculosis.
4. Indication:  Not Available
DrugId:  18
1. Name:  Viomycin
2. Groups:  Approved
3. Description:  Viomycin is a member of the tuberactinomycin family, a group of nonribosomal peptide antibiotics exhibiting anti-tuberculosis properties. The tuberactinomycin family is an essential component in the drug cocktail currently used to fight infections of Mycobacterium tuberculosis. Viomycin was the first member of the tuberactinomycins to be isolated and identified and was used to treat TB until it was replaced by the less toxic, but structurally related compound, capreomycin. The tuberactinomycins target bacterial ribosomes, binding RNA and disrupting bacterial protein biosynthesis. It is produced by the actinomycete Streptomyces puniceus, that binds to RNA and inhibits prokaryotic protein synthesis and certain forms of RNA splicing. [Wikipedia]
4. Indication:  Viomycin is an essential component in the drug cocktail currently used to fight infections of Mycobacterium tuberculosis.
DrugId:  19
1. Name:  Faropenem
2. Groups:  Investigational
3. Description:  Faropenem has been used in trials studying the treatment of Tuberculosis, Pulmonary Tuberculosis, and Community Acquired Pneumonia.
4. Indication:  Not Available
DrugId:  20
1. Name:  Aminosalicylic Acid
2. Groups:  Approved
3. Description:  An antitubercular agent often administered in association with isoniazid. The sodium salt of the drug is better tolerated than the free acid.
4. Indication:  For the treatment of tuberculosis
DrugId:  21
1. Name:  Bexarotene
2. Groups:  Approved, Investigational
3. Description:  Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. [Wikipedia]
4. Indication:  Used orally for the treatment of skin manifestations of cutaneous T-cell lymphoma (CTCL) in patients who are refractory to at least one prior systemic therapy. Also used topically for the treatment of skin lesions in early (stage IA and IB) CTCL in patients who experience refractory or persistent disease with the use of other therapies or are intolerant of other therapies.
DrugId:  22
1. Name:  Bedaquiline
2. Groups:  Approved
3. Description:  Bedaquiline is a bactericidal antimycobacterial drug. Chemically it is a diarylquinoline. FDA approved on December 28, 2012. 
4. Indication:  Bedaquiline is indicated as part of combination therapy in adults (â‰¥ 18 years) with pulmonary multi-drug resistant tuberculosis (MDR-TB). 
DrugId:  23
1. Name:  AFN-1252
2. Groups:  Investigational
3. Description:  AFN-1252 has been used in trials studying the treatment of Cellulitis, Burn Infection, Wound Infection, Cutaneous Abscess, and Skin and Subcutaneous Tissue Bacterial Infections.
4. Indication:  Not Available
DrugId:  24
1. Name:  ALGRX 1207
2. Groups:  Investigational
3. Description:  ALGRX 1207 is a topical local anesthetic that acts by binding to the fast sodium channel. ALGRX 1207 entered clinical trials for cutaneous neuropathic pain, such as chemotherapy-induced neuropathy, in 2006. It was being developed by Anesiva, but trials have halted.
4. Indication:  Investigated for use/treatment in pain (acute or chronic).
DrugId:  25
1. Name:  Isoniazid
2. Groups:  Approved, Investigational
3. Description:  Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. [PubChem]
4. Indication:  For the treatment of all forms of tuberculosis in which organisms are susceptible.
